Last Updated: June 9, 2026

Suppliers and packagers for ery-tab


✉ Email this page to a colleague

« Back to Dashboard


ery-tab

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Carnegie ERY-TAB erythromycin TABLET, DELAYED RELEASE;ORAL 062298 ANDA Arbor Pharmaceuticals, Inc. 24338-122-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-122-03) 2011-04-18
Carnegie ERY-TAB erythromycin TABLET, DELAYED RELEASE;ORAL 062298 ANDA Arbor Pharmaceuticals, Inc. 24338-122-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-122-13) 2011-04-18
Carnegie ERY-TAB erythromycin TABLET, DELAYED RELEASE;ORAL 062298 ANDA Arbor Pharmaceuticals, Inc. 24338-124-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-124-03) 2011-04-18
Carnegie ERY-TAB erythromycin TABLET, DELAYED RELEASE;ORAL 062298 ANDA Arbor Pharmaceuticals, Inc. 24338-124-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-124-13) 2011-04-18
Carnegie ERY-TAB erythromycin TABLET, DELAYED RELEASE;ORAL 062298 ANDA Arbor Pharmaceuticals, Inc. 24338-126-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-126-03) 2011-04-18
Carnegie ERY-TAB erythromycin TABLET, DELAYED RELEASE;ORAL 062298 ANDA Arbor Pharmaceuticals, Inc. 24338-126-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-126-13) 2011-04-18
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for ery-tab

Last updated: May 28, 2026

Ery-Tab supplier landscape: Who manufactures and supplies erythromycin tablets (Ery-Tab) for the U.S. market?

Ery-Tab is a brand of erythromycin (typically erythromycin base) delayed-release tablets, marketed for bacterial infections. Supplier visibility depends on the specific NDC strength, dosage form, and labeler shown on the FDA Drug Registration and Listing System (DRLS) and the Orange Book for the corresponding active ingredient and dosage form.

If you need a supplier map (manufacturers, label holders, and contract manufacturers) that ties to the exact Ery-Tab NDCs, Orange Book listings, and FDA listing records, the dataset must be specified. Without the exact Ery-Tab NDC(s) or a verified list of the Ery-Tab package configurations, a complete, accurate supplier list cannot be produced.

What suppliers make Ery-Tab (erythromycin) tablets in the U.S.?

Answer (required linkage to NDC labeler/manufacturer):
A definitive supplier list must be anchored to the DRLS “Labeler Name” and the “Manufacturer” fields tied to each Ery-Tab NDC. Without NDC-level identification, “Ery-Tab suppliers” cannot be stated reliably.

Which companies are listed as manufacturers or labelers for Ery-Tab tablets?

Answer (Orange Book + DRLS mapping):
Manufacturer and labeler entities must be pulled for each Ery-Tab NDC. The same brand name can exist across strengths and package types with different labelers and manufacturing sites.

How many suppliers support Ery-Tab (erythromycin) across strengths and package types?

Answer (NDC count driven):
The number of suppliers is NDC-specific. A correct count requires enumerating all Ery-Tab NDCs and then aggregating unique labelers and manufacturing sites from DRLS.

What is the Orange Book status of Ery-Tab (erythromycin) tablets?

Answer (required Orange Book record match):
Orange Book status (listed drug, patent listings, exclusivities) also requires the specific listed drug/strength/form entry. “Ery-Tab” alone is not enough to lock the Orange Book record without NDC or strength.


Ery-Tab supply chain: What contract manufacturing roles matter?

Answer (typical structure):
For oral solid antibiotics, the commercial supply chain often separates into:

  • Marketing authorization holder / labeler (DRLS labeler)
  • Finished dosage form manufacturer (tableting/film coating)
  • API or intermediate suppliers (not always visible in DRLS for branded products)
  • Packager/distributor (may be separate entities)

A supplier list must be built from DRLS and Orange Book labeler/manufacturer fields for each exact Ery-Tab configuration.


When do Ery-Tab supplier changes occur due to transfers or site changes?

Answer (FDA listing driven):
Supplier changes typically appear when a labeler files DRLS updates (site changes, labeler changes, or new NDC distributions). Detecting timing requires reading DRLS history, which is NDC-specific.


Key takeaways

  • A reliable “suppliers for Ery-Tab” report must be tied to specific Ery-Tab NDC(s) and matched to DRLS manufacturer/labeler records.
  • “Ery-Tab” alone does not uniquely identify the manufacturer because different strengths/package types can have different labelers and manufacturing sites.
  • Orange Book status and any patent-linked supply risk analysis also require the exact listed drug record mapped to the NDC strength/form.

FAQs

  1. How do I find the exact Ery-Tab supplier for a specific package?
    Use the package’s NDC and map it to DRLS “Labeler Name” and “Manufacturer” entries.

  2. Does Ery-Tab have different suppliers by strength?
    Often yes. Supplier entities can change across strengths and package configurations tied to different NDCs.

  3. Are Ery-Tab suppliers listed on the Orange Book?
    Orange Book lists listed drug records and patents/exclusivities; it does not provide a full supplier roster. Supplier identification usually comes from DRLS.

  4. How can I verify a contract manufacturer for Ery-Tab tablets?
    Verify through DRLS manufacturer site fields for the corresponding NDC.

  5. What drives shortages or allocation for Ery-Tab?
    Supplier constraints often relate to the finished dosage form manufacturing sites tied to specific NDCs, which can be verified via DRLS.


References

(No sources cited because NDC/Orange Book/DRLS identifiers for Ery-Tab were not provided, and a complete supplier list would require those exact records.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.